Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 18;6(2):169-73.
doi: 10.3980/j.issn.2222-3959.2013.02.12. Print 2013.

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients

Jun Li  1 , Han Zhang, Peng Sun, Feng Gu, Zhe-Li Liu
Affiliations

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients

Jun Li et al. Int J Ophthalmol. .

Abstract

Aim: To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age-related macular degeneration (AMD).

Methods: Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1.25mg) and 32 received intravitreal ranibizumab injections (0.5mg), once a month for 3 months and were followed for a total of 6 months. Monthly optical coherence tomography (OCT) was used to determine whether the patients received additional treatments during the follow-up. We compared the baseline and 6-month follow-up values of mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in both groups of patients. We also compared the occurrence of adverse events.

Results: At the 6-month follow-up, the mean BCVA (logMAR) of the bevacizumab and ranibizumab treatment groups improved from the baseline measurements of 0.72±0.23 and 0.73±0.22 to 0.47±0.14 and 0.45±0.20, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. As evaluated by OCT, CRT decreased from 366.71±34.72µm and 352±36.9µm at baseline to 250.86±41.51µm and 243.22±41.38µm in the bevacizumab and ranibizumab groups, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. There were no severe local adverse reactions or systemic adverse events.

Conclusion: Intravitreal bevacizumab and ranibizumab have equivalent effects on BCVA and CRT and appeare safe over the short-term.

Keywords: age-related macular degeneration; bevacizumab (avastin); choroidal neovascularization; ranibizumab (lucentis).

PubMed Disclaimer

Figures

Figure 1
Figure 1. BCVA changes over 6 months.
Error bars represent 95% confidence interval (CI).
Figure 2
Figure 2. CRT changes over 6 months.
Error bars represent 95% confidence intervals (CI).
Figure 3
Figure 3. Incidence of adverse events.
See this image and copyright information in PMC

References

    1. Zou HD, Zhang X, Xu X, Wang FH, Zhang SJ. Age-related macular degeneration prevalence survey of Caojiadu street Jing'an district in Shanghai. ZhonghuaYanke Zhazhi. 2005;41(1):15–19. - PubMed
    1. Lou ZL, Chen G, Tang R. Age-related macular degeneration prevalence survey of agency personnel in Changsha city. Ophthalmol Res. 2008;26(11):822–823.
    1. Ni Z. 1st edition. Shanghai: Shanghai Scientific Popularization Publishing House; 2002. Pathological anatomy and clinical of ophthalmology; pp. 281–282.
    1. Sheng YJ. Advances in the treatment of age-related macular degeneration. J Clin Ophthalmol. 2004;12(5):471.
    1. Bressler NM. Antiangiogenic approaches to aged-related macular degeneration today. Ophthalmology. 2009;116(10 Suppl):S15–23. - PubMed